Increasing TMEM106B levels by over-expression inhibits lysosomal transport (Stagi et al. 2014), which is consistent with our findings that an FTD-causing mutation in CHMP2B also decreases lysosomal transport. Here, CHMP2B is linked to frontotemporal dementia.